ClinicalTrials.gg

Program

zongertinib

Also written as “Zongertinib”, “zongertinib (C-14)” and “Zongertinib, Formulation A, reference product”.

Its studies are mostly in Lung Neoplasms · Breast Neoplasms · Neoplasm Metastasis · Liver Diseases · Carcinoma, Non-Small-Cell Lung, led by Boehringer Ingelheim.

Furthest: phase 3, since Nov 22, 202315 company-led studies, 7 open or runningNext primary completion: Dec 10, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim157 open or runningphase 3since Nov 22, 2023May 4, 2021Dec 10, 2026phase 3 · NCT06151574

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since May 4, 2021.

  1. Feb 28, 2023Phase 1 study in HealthyNCT05833139 · 16 enrolled · Germany
  2. May 25, 2023Phase 1 study in HealthyNCT05879991 · 15 enrolled · Netherlands
  3. Aug 30, 2023Phase 1 study in HealthyNCT06028464 · 16 enrolled · Germany
  4. Oct 4, 2023Phase 1 study in HealthyNCT06075277 · 16 enrolled · Germany
  5. Nov 22, 2023Phase 3 study in Lung NeoplasmsNCT06151574 · 428 enrolled · United States, Argentina, Australia and more
  6. Mar 15, 2024Phase 2 study in Breast NeoplasmsNCT06324357 · 910 planned · United States, Belgium, China and more
  7. Jul 3, 20242 phase 1 studies in HealthyNCT06494761, NCT06504862
  8. Aug 30, 2024Phase 2 study in Solid TumoursNCT06581432 · 588 planned · United States, Australia, Belgium and more
  9. Nov 15, 2024Phase 1 study in Liver DiseasesNCT06692322 · 29 enrolled · United States
  10. Sep 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07195695 · 400 planned · United States, Argentina, Australia and more
  11. Mar 12, 2026Phase 2 study in Lung NeoplasmsNCT07486817 · 60 planned · Australia, China, France and more
  12. Jun 11, 2026Phase 1 study in HealthyNCT07649941 · 16 enrolled · Germany
  13. Aug 24, 2026Phase 1 study in HealthyNCT07789028 · 56 planned · Germany
  14. Oct 28, 2026Primary completion moved from 2026-12-30 to 2028-02-29Date moved laterphase 1 · +14 months · NCT04886804

Ahead

  1. Dec 10, 2026Primary completion: phase 3 study in Lung NeoplasmsNCT06151574
  2. Dec 15, 2026Primary completion: phase 1 study in HealthyNCT07789028
  3. Aug 12, 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07486817
  4. Feb 29, 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT04886804

TargetBeta

ERBB2 →read by rule
“An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07789028Healthy · Germany1RecruitingDec 15, 202656
NCT07649941Healthy · Germany1CompletedJul 31, 202616
NCT07486817Lung Neoplasms · Australia, China, France and more2RecruitingAug 12, 202760
NCT07195695Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingFeb 26, 2032400
NCT06692322Liver Diseases · United States1CompletedJun 20, 202529
NCT06581432Solid Tumours · United States, Australia, Belgium and more2RecruitingNov 30, 2028588
NCT06504862Healthy · Germany1CompletedOct 3, 202432
NCT06494761Healthy · Germany1CompletedOct 16, 202416
NCT06324357Breast Neoplasms · United States, Belgium, China and more2RecruitingJan 8, 2029910
NCT06151574Lung Neoplasms · United States, Argentina, Australia and more3Active, not recruitingDec 10, 2026428
NCT06075277Healthy · Germany1CompletedJan 2, 202416
NCT06028464Healthy · Germany1CompletedDec 8, 202316
NCT05879991Healthy · Netherlands1CompletedOct 19, 202315
NCT05833139Healthy · Germany1CompletedJun 12, 202316
NCT04886804Neoplasm Metastasis · United States, Australia, Austria and more1RecruitingFeb 29, 2028554

How it is read

Names in the registry

  • “Zongertinib”, 9 entries
  • “zongertinib”, 5 entries
  • “zongertinib (C-14)”, 2 entries
  • “Zongertinib, Formulation A, reference product”, 1 entry
  • “Zongertinib Formulation B, test product”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.